RAPT Therapeutics, Inc. (RAPT) EBITDA (2020 - 2024)
RAPT Therapeutics' EBITDA history spans 5 years, with the latest figure at -$53.3 million for Q4 2024.
- For Q4 2024, EBITDA fell 73.91% year-over-year to -$53.3 million; the TTM value through Dec 2024 reached -$129.9 million, down 11.36%, while the annual FY2024 figure was -$129.9 million, 11.36% down from the prior year.
- EBITDA for Q4 2024 was -$53.3 million at RAPT Therapeutics, down from -$18.3 million in the prior quarter.
- Across five years, EBITDA topped out at -$12.2 million in Q2 2020 and bottomed at -$53.3 million in Q4 2024.
- The 5-year median for EBITDA is -$19.9 million (2022), against an average of -$22.6 million.
- The largest YoY upside for EBITDA was 41.63% in 2024 against a maximum downside of 73.91% in 2024.
- A 5-year view of EBITDA shows it stood at -$13.0 million in 2020, then crashed by 40.0% to -$18.2 million in 2021, then dropped by 23.89% to -$22.5 million in 2022, then plummeted by 36.09% to -$30.7 million in 2023, then plummeted by 73.91% to -$53.3 million in 2024.
- Per Business Quant, the three most recent readings for RAPT's EBITDA are -$53.3 million (Q4 2024), -$18.3 million (Q3 2024), and -$27.7 million (Q2 2024).